LIPI Stock Overview
A pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Lipidor AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.12 |
| 52 Week High | SEK 1.35 |
| 52 Week Low | SEK 0.04 |
| Beta | 0.62 |
| 11 Month Change | -21.21% |
| 3 Month Change | 48.10% |
| 1 Year Change | -83.97% |
| 33 Year Change | -98.71% |
| 5 Year Change | -99.11% |
| Change since IPO | -98.26% |
Recent News & Updates
Recent updates
We're Hopeful That Lipidor (STO:LIPI) Will Use Its Cash Wisely
Sep 04
Lipidor (STO:LIPI) Is In A Strong Position To Grow Its Business
Feb 24We Think Lipidor (STO:LIPI) Can Afford To Drive Business Growth
Sep 15Here's Why We're Not At All Concerned With Lipidor's (STO:LIPI) Cash Burn Situation
May 13Companies Like Lipidor (STO:LIPI) Are In A Position To Invest In Growth
Jan 29Need To Know: Lipidor AB (publ) (STO:LIPI) Insiders Have Been Selling Shares
Dec 07
Shareholder Returns
| LIPI | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -11.7% | -5.5% | -2.4% |
| 1Y | -84.0% | 9.1% | 10.9% |
Return vs Industry: LIPI underperformed the Swedish Pharmaceuticals industry which returned 9.1% over the past year.
Return vs Market: LIPI underperformed the Swedish Market which returned 10.9% over the past year.
Price Volatility
| LIPI volatility | |
|---|---|
| LIPI Average Weekly Movement | 13.9% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: LIPI's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: LIPI's weekly volatility has decreased from 30% to 14% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 5 | Ola Holmlund | lipidor.se |
Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, AKP-03 for bacterial skin diseases, and AKP-07 for atopic dermatitis. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine.
Lipidor AB (publ) Fundamentals Summary
| LIPI fundamental statistics | |
|---|---|
| Market cap | SEK 97.20m |
| Earnings (TTM) | -SEK 13.53m |
| Revenue (TTM) | SEK 93.00k |
1,023x
P/S Ratio-7.0x
P/E RatioIs LIPI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIPI income statement (TTM) | |
|---|---|
| Revenue | SEK 93.00k |
| Cost of Revenue | SEK 9.26m |
| Gross Profit | -SEK 9.17m |
| Other Expenses | SEK 4.36m |
| Earnings | -SEK 13.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 28, 2025
| Earnings per share (EPS) | -0.017 |
| Gross Margin | -9,861.29% |
| Net Profit Margin | -14,546.24% |
| Debt/Equity Ratio | 0% |
How did LIPI perform over the long term?
See historical performance and comparison